82059
document
The antiemetic efficacy of prophylactic granisetron in gynecologic surgery . Postoperative nausea and vomiting are common after recovery from anesthesia . We examined the prophylactic effect of granisetron on postoperative nausea and vomiting in 120 female patients ( ASA physical status I ) undergoing gynecologic surgery . They were randomly allocated to one of three groups ( n = 40 for each ) : saline ( as a control ) , granisetron 20 micrograms/kg , and granisetron 40 micrograms/kg . Saline or granisetron was given intravenously ( IV ) over 5 min approximately 30 min before the end of anesthesia . Nausea , vomiting , and safety assessments were performed during the 24-h recovery period . For the 24-h period after surgery , the number of emesis-free patients was significantly larger in the granisetron groups than in the control group ( 83 % , 78 % , and 20 % of patients receiving granisetron 20 micrograms/kg and 40 micrograms/kg , and saline , respectively ) . Granisetron at both doses also was superior to the control for the prevention of nausea over the 24-h study period ( nausea visual analog scales at 24-h postsurgery : 49 mm , 17 mm , and 18 mm in the control , granisetron 20 micrograms/kg , and granisetron 40 micrograms/kg groups , respectively ) . Fewer patients received " rescue " antiemetics in the granisetron groups than in the control group ( 10 % , 10 % , and 43 % of patients in granisetron 20 micrograms/kg and 40 micrograms/kg , and the control groups , respectively ) . The adverse events in the granisetron groups were similar to those in the control group . The administration of granisetron had no significant effect on vital signs or clinical laboratory test profiles . Granisetron given at 20 or 40 micrograms/kg i.v . during anesthesia appears to be a simple , effective , and safe method for preventing postoperative nausea and vomiting .
82060
Intervention_Pharmacological
prophylactic granisetron
82061
Intervention_Pharmacological
granisetron
82062
Intervention_Pharmacological
saline
82063
Intervention_Pharmacological
granisetron
82064
Intervention_Pharmacological
granisetron
82065
Intervention_Pharmacological
Saline
82066
Intervention_Pharmacological
granisetron
82067
Intervention_Pharmacological
Granisetron
82068
Intervention_Pharmacological
granisetron
82069
Intervention_Pharmacological
granisetron
82070
Intervention_Pharmacological
granisetron
82071
Intervention_Pharmacological
Granisetron
82072
Outcome_Other
antiemetic efficacy
82073
Outcome_Adverse-effects
Postoperative nausea and vomiting
82074
Outcome_Adverse-effects
postoperative nausea and vomiting
82075
Outcome_Adverse-effects
Nausea , vomiting
82076
Outcome_Other
safety assessments
82077
Outcome_Other
number of emesis-free patients
82078
Outcome_Adverse-effects
nausea
82079
Outcome_Adverse-effects
nausea visual analog scales
82080
Outcome_Physical
" rescue " antiemetics
82081
Outcome_Adverse-effects
adverse events
82082
Outcome_Physical
vital signs
82083
Outcome_Other
or
82084
Outcome_Physical
clinical laboratory test profiles
82085
Outcome_Other
simple , effective , and safe method
82086
Outcome_Adverse-effects
postoperative nausea and vomiting
82087
Participant_Condition
gynecologic surgery .
82088
Participant_Condition
recovery from anesthesia .
82089
Participant_Condition
120 female patients ( ASA physical status I ) undergoing gynecologic surgery .